News
NBIX
134.66
-1.01%
-1.37
Neurocrine Biosciences Inc: Report of proposed sale of securities
Press release · 1d ago
Selection Of The Development Candidate For Friedreich's Ataxia in Collaboration with Neurocrine Biosciences Triggered $5M Milestone Payment To Voyager, Which It Expects To Receive In The First Quarter Of 2024
Benzinga · 3d ago
Voyager Therapeutics Announced That The Joint Steering Committee With Its Collaborator Neurocrine Biosciences Has Selected A Lead Development Candidate In Friedreich's Ataxia Program. The Companies Expect The Program To Advance Into Human Trials In 2025
Benzinga · 3d ago
Weekly Report: what happened at NBIX last week (0219-0223)?
Weekly Report · 3d ago
IVOG: Mid-Cap Growth ETF Outperforming Peers In 2024
Vanguard S&P Mid-Cap 400 Growth Index Fund ETF Shares uses sales growth, earnings growth, and momentum to select stocks. The IVOG ETF overweights industrials and underweights financials compared to the parent index. IVOG's performance is average among peers over the past 5 years but has outperformed in 2024.
Seeking Alpha · 5d ago
RBC Capital Keeps Their Hold Rating on Neurocrine (NBIX)
TipRanks · 02/22 12:32
Weekly Report: what happened at NBIX last week (0212-0216)?
Weekly Report · 02/19 09:06
14 buy-rated Stocks with big improvements in their ROE - Jefferies
14 buy-rated Stocks with big improvements in their ROE - Jefferies highlighted 14 stocks with strong momentum. The list was inspired by Jefferies' Equity Strategy report. Electronic Arts and Dave & Buster’s are among the companies on the list. Jefferies says the companies have improved their return on equity in the past year.
Seeking Alpha · 02/16 18:50
3 Pharma Stock Buys With Accelerating Gains
Neurocrine Biosciences, Inc. (NBIX), AstraZeneca PLC (AZN) and Johnson & Johnson (JNJ) are fundamentally strong pharma stocks. The pharmaceutical industry is expected to thrive as demand increases and technology advances. The three stocks are expected to be ideal additions to your portfolio for gains.
Barchart · 02/15 12:14
Neurocrine Biosciences Inc: Report of proposed sale of securities
Press release · 02/14 01:15
Positive Outlook for Neurocrine Biosciences with Underappreciated Pipeline Potential
TipRanks · 02/13 10:41
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Shares of Teva Pharmaceutical Industries Ltd (TEVA) spiked 6.82% to $12.84 in early trading on Monday. Several analysts raised their forecasts for the company. Piper Sandler upgraded the rating for Teva from Neutral to Overweight. The stock seems poised for a recovery due to the Austedo franchise and improved positioning of the U.S. Generics business.
Benzinga · 02/12 16:53
Weekly Report: what happened at NBIX last week (0205-0209)?
Weekly Report · 02/12 09:05
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Seeking Alpha · 02/11 01:30
Neurocrine Biosciences: A Strong Buy on Robust Financial Performance and Promising Drug Pipeline
TipRanks · 02/09 05:56
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Sarepta Therapeutics (SRPT) and Neurocrine (NBIX)
TipRanks · 02/09 05:51
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Seeking Alpha · 02/08 21:30
More
Webull provides a variety of real-time NBIX stock news. You can receive the latest news about Neurocrine Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.